NPPA denies price hike on Sanofi, Novartis, and Allergan products.
Patients' lobbies cheer ruling on anti-cancer drug Glivec, as affordability and access to life-saving drugs get a leg-up.
In yet another setback to Swiss drug multinational Novartis AG, the Indian patent office has rejected its application to secure a patent for an alfa crystal form of its blockbuster cancer medicine, Glivec.
Ranbaxy was scheduled to launch its drug on September 21, the day Diovan's patent expired.
Today, apologies by CEOs of global corporations have become so common that you get case studies on the subject.
Novartis India invites students to participate in the 2nd Biotechnology Leadership Camp (BioCamp) taking place in Hyderabad from July1 to 3, 2010.
Ajit Mishra, vice president, research, Religare Broking, answers your queries.
Global pharma majors such as Novartis, Roche and Pfizer have secured 392 medicine patents in less than three years of India changing its patent laws to allow product patenting system for drugs in the country. While Swiss multinational Hoffmann La Roche leads the tally with 34 patent grants, Novartis AG and Pfizer Inc follow closely with 25 and 24 respectively.
The merger of Pfizer and Wyeth is expected to create the second-biggest drug maker among multinational companies in India. The world's largest drug maker Pfizer yesterday announced a $68-billion acquisition of US-based Wyeth.
Besides Novartis, the other companies are Roche, J&J, Glaxo and Astrazeneca.
The Fortune's 40 under 40 list for this year was topped by Adam Neuman, Co-founder and CEO, WeWork.
The worry is that India's cavalier approach to intellectual property may catch on in other parts of the developing world
In spite of all their complaints, pharma MNCs have been gaining market share in India. And this growth has come largely with generics.
Though the legal battle over Glivec's patentability may be over for now, Y K Sapru, the man spearheading the fight against Swiss multinational Novartis, isn't resting.
Supreme Court will give its verdict on April 1 on whether Swiss giant Novartis AG's cancer treatment drug Glivec deserves a patent in the country not it doesn't.
If it gets the USFDA nod, the sales would help to pull the company out of the red.
People die from diseases like AIDS, TB, etc because life saving essential medicines are either too expensive, or not available because they are not seen as financially viable.
Closure would mean manufacturer might not be able to launch any new generic products in India in future.
In his last assignment, he led the global product strategy and commercialisation functions at Novartis Pharma AG.
Companies say they follow global standards in India as well
Employees allege forcible layoffs; firm says ensuring it "best maximises performance and optimises resources"
With as many as 2,868 deaths during clinical trials from 2005 to 2012, only 89 have been attributed directly to such trials and compensation paid only in 45 cases so far, the Rajya Sabha was informed.
At a time when pharmaceutical companies are investing billions of dollars to develop new and path-breaking medicines, it is the old and heritage brands that continue to dominate the market. Sales in 2011 show that the average age of the top 10 pharma brands is 19.3 years, and some of them are as old as 25 years.
Eight commonly prescribed anti-cancer drugs will soon enter India's National List of Essential Medicines (NLEM).
The ministry has asked 44 pharmaceutical companies, including global drug majors such as Eli Lilly, Novartis, Pfizer, Bayer, Merck, Johnson & Johnson and Sanofi Aventis, to explain why they have not given the compensation, which is mandatory under the current drug laws.
According to Dr Reddy's, the drugmaker may launch Rivastigmine, an anti-mild-to-moderate Alzheimer's drug, Desloratadine, used to treat allergies and Pseudoephedrine, a nasal/sinus decongestant.
The National Pharmaceutical Pricing Authority, which regulates the prices of medicines, has identified around 70 anti-cancer drugs, including anti-breast cancer medication Letrozole and anti-blood cancer drug Imatinib, for detailed price analysis.
The footprints of Indian-origin corporate executives at multinationals is expanding, with Sandeep Kataria taking over the reins of footwear major Bata as its global chief executive officer. From FMCG majors to IT titans, Kataria joins the league of Indian-origin executives who have climbed the highest echelons of corporate across diverse sectors globally. From Nooyi to Pichai to Nadella, the list of such people at the helm of multi-billion dollar enterprises is long.
The first-ever study conducted by the National Pharmaceutical Pricing Authority (NPPA) on cancer medicines has found huge price variations among different brands of same medicines sold in the country.
Communications between the USTR and the world's most powerful pharmaceutical and trade lobbying groups reveal that many raised concerns about India's push to exempt Covid vaccines from intellectual property.
Aurobindo pharma, cipla, orchid chemicals are the prominent takeover targets.
These include former drugs controller M Venkateshwarlu, Ranbaxy CMD Malvinder Mohan Singh, Ranjit Shahani, India chief of Swiss pharma major Novartis AG, Ramaprasad Reddy, chairman Aurobindo Pharma and Rajesh Jain, joint managing director, Panacea Biotec.
Eminent Indian-origin academician Srikant Datar has been named as Dean of Harvard Business School, succeeding Nitin Nohria and becoming the second consecutive dean hailing from India to lead the prestigious 112-year-old institution. Datar, an alumnus of University of Bombay and Indian Institute of Management, Ahmedabad, is the Arthur Lowes Dickinson Professor of Business Administration and the senior associate dean for University Affairs at Harvard Business School (HBS). He will assume charge as the school's next dean on January 1, president Larry Bacow said.
The Clinical Research sector is emerging as an attractive option for science graduates, doctors, management/ IT professionals, alike.
Manufacturers warned on Wednesday that limited stocks of a future swine flu vaccine could be distributed on a "first come, first served" basis, leaving hundreds of millions of people in poorer countries without protection.
Drug major Wockhardt has challenged the US patent of Stalevo, a new generation combination drug for the treatment of Parkinson's disease, originated by Finland-based Orion Corporation and marketed by Novartis.
India is not so keen to co-operate with the US on IPR related probe.
Despite the best efforts of Indian vaccine makers to develop the H1N1(swine flu) vaccine, Swiss drug major Novartis and Australian vaccine maker CSL may be the first ones to bag the orders from the central government for its supply.
Delegation visit ahead of patent law report.
There is no doubt that patients are the ultimate beneficiaries of pharmaceutical research and development. Thousands of public health needs go unmet each day simply because there is still a cure out there waiting to be found. Product patents serve as encouragement to innovation, providing impetus to both investors and innovators. It has been argued that by denying product patents, India will encourage domestic generic production and, therefore, access to medicines.
© 2026 Rediff.com - Investor Information - Advertise with us - Disclaimer - Privacy Policy - Sitemap - Feedback - About us - Terms of use - Grievances